Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can clot removal help even the largest strokes?

NCT ID NCT07791810

Disease control Sponsor: First Affiliated Hospital of Harbin Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether a procedure to remove blood clots from the brain, called endovascular treatment, can improve recovery in people who have had a severe stroke with a very large area of brain damage. Participants receive either the clot-removal procedure plus standard medical care, or standard medical care alone. The study tracks how well people recover over 90 days and up to 180 days after the stroke.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endovascular treatment (mechanical thrombectomy) to remove blood clots from large brain arteries
What this could lead to
If it works, this could expand treatment options for people with severe strokes and very large areas of brain damage, potentially improving their recovery and independence.
What could go wrong
The trial is early and the treatment carries risks, including bleeding or vessel damage. The benefit may not outweigh these risks for all patients, and results may not apply to everyone with this type of stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years. 2. Symptoms onset or Time last known well ≤ 24 h from randomization. 3. Acute ischemic stroke due to an occlusion of the intracranial internal carotid artery, M1 or proximal M2 segment of the middle cerebral artery confirmed by CTA or MRA. 4. NCCT or diffusion-weighted imaging (DWI) demonstrating ASPECTS ≤ 2 or infarct core volume (defined as rCBF \<30% on CTP) ≥ 100 mL. 5. Selection imaging performed ≤ 3 hours before randomization. 6. Pre-stroke mRS 0 - 1. 7. Informed consent form was signed. Exclusion Criteria: 1. Evidence of intracranial hemorrhage on CT/MRI, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, or subdural/epidural hemorrhage. 2. Cerebral midline shift or herniation, or other ventricular mass effect with midline shift as confirmed on CT/MRI. 3. Bilateral anterior circulation or acute multi-vessel occlusion involving both anterior and posterior circulation, confirmed by CTA or MRA. 4. Blood pressure \>185/110 mmHg and is refractory to medicine. 5. Known coagulopathy, with international normalized ratio (INR) \>1.7 or platelet count \<100×10⁹/L; 6. Current treatment with direct thrombin inhibitors or factor Xa inhibitors; 7. Patients with severe organ failure (cardiac, pulmonary, renal, or hepatic); 8. Concomitant malignancy or other conditions with life expectancy under 6 months; 9. Female who is known to be pregnant; 10. Prior endovascular attempt for this stroke;; 11. Currently participation in another clinical study; 12. Other circumstances that the investigator considers inappropriate for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma in situ stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AIS Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • he First Affiliated Hospital of Harbin Medical University

    Harbin, Hei Longjiang, 150001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.